Cargando…

Metabolic Imaging in B-Cell Lymphomas during CAR-T Cell Therapy

SIMPLE SUMMARY: Chimeric antigen receptor–engineered T cells are an innovative therapy in hematologic malignancies, especially in patients with refractory/relapsed B-cell lymphomas. Few studies have analyzed the role of [(18)F]FDG PET/CT in this field; this review aims to illustrate the literature d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Linguanti, Flavia, Abenavoli, Elisabetta Maria, Berti, Valentina, Lopci, Egesta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562671/ https://www.ncbi.nlm.nih.gov/pubmed/36230629 http://dx.doi.org/10.3390/cancers14194700

Ejemplares similares

Advances in Lung Cancer Imaging and Therapy
por: Lopci, Egesta, et al.
Publicado: (2021)

Impact of Antibiotic Therapy and Metabolic Parameters in Non-Small Cell Lung Cancer Patients Receiving Checkpoint Inhibitors
por: Castello, Angelo, et al.
Publicado: (2021)

More than Just Skin-Deep: A Review of Imaging’s Role in Guiding CAR T-Cell Therapy for Advanced Melanoma
por: Prendergast, Conor M., et al.
Publicado: (2023)

Characterization of Mediastinal Bulky Lymphomas with FDG-PET-Based Radiomics and Machine Learning Techniques
por: Abenavoli, Elisabetta Maria, et al.
Publicado: (2023)

Editorial: Response assessment of radioligand therapies
por: Lopci, Egesta, et al.
Publicado: (2022)

Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study
por: Linguanti, Flavia, et al.
Publicado: (2022)

CAR T-Cell Therapy for Large B-Cell Lymphoma
por: Alencar, Maritza C.
Publicado: (2019)

CAR-T Cell Therapy in Large B Cell Lymphoma
por: Testa, Ugo, et al.
Publicado: (2023)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [(18)F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Lopci, Egesta
Publicado: (2021)

Meditating on Cancer Management at the Time of Immunotherapy
por: Lopci, Egesta
Publicado: (2022)

18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art
por: Castello, Angelo, et al.
Publicado: (2020)

Cellular Therapy Updates in B-Cell Lymphoma: The State of the CAR-T
por: Crees, Zachary D., et al.
Publicado: (2021)

Adapter CAR T Cell Therapy for the Treatment of B-Lineage Lymphomas
por: Atar, Daniel, et al.
Publicado: (2022)

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1
por: Castello, Angelo, et al.
Publicado: (2020)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

Circulating Tumor Cells and Metabolic Parameters in NSCLC Patients Treated with Checkpoint Inhibitors
por: Castello, Angelo, et al.
Publicado: (2020)

Metabolism of Stem and Progenitor Cells: Proper Methods to Answer Specific Questions
por: Martano, Giuseppe, et al.
Publicado: (2019)

Impact of the COVID-19 pandemic in nuclear medicine departments: preliminary report of the first international survey
por: Annunziata, Salvatore, et al.
Publicado: (2020)

CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain
por: Li, Tongjuan, et al.
Publicado: (2020)

CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope
por: Hopfinger, Georg, et al.
Publicado: (2019)

Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma
por: Zurko, Joanna, et al.
Publicado: (2022)

Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors and Its Correlation with Metabolic Parameters
por: Castello, Angelo, et al.
Publicado: (2020)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

The Role of 18F-FDG PET/CT in Staging and Prognostication of Mantle Cell Lymphoma: An Italian Multicentric Study
por: Albano, Domenico, et al.
Publicado: (2019)

CAR T-Cell therapy for the management of mantle cell lymphoma
por: Huang, Zoufang, et al.
Publicado: (2023)

CD19 directed CAR T cell therapy in diffuse large B-cell lymphoma
por: Quintás-Cardama, Alfonso
Publicado: (2018)

CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
por: Chavez, Julio C., et al.
Publicado: (2019)

The role of CAR-T cell therapy as second line in diffuse large B-cell lymphoma
por: Albanyan, Omar, et al.
Publicado: (2022)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

Recent advances in CAR T-cell therapy for lymphoma in China
por: Che, Yuxuan, et al.
Publicado: (2023)

CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma
por: Su, Lihe, et al.
Publicado: (2022)

Prognostic Value of Metabolic Imaging Data of (11)C-choline PET/CT in Patients Undergoing Hepatectomy for Hepatocellular Carcinoma
por: Donadon, Matteo, et al.
Publicado: (2021)

Assessing and Management of Neurotoxicity After CAR-T Therapy in Diffuse Large B-Cell Lymphoma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

Imaging with non-FDG PET tracers: outlook for current clinical applications
por: Lopci, Egesta, et al.
Publicado: (2010)

P034: Correlation between MTV, TLG and Serum TARC Concentration in Classical Hodgkin Lymphoma during First-Line Treatment
por: Romano, Ilaria, et al.
Publicado: (2022)

Anti-CD19 CAR T-Cell Therapy for Adult Patients With Refractory Large B-Cell Lymphoma
por: McDermott, Kathleen, et al.
Publicado: (2019)

Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia
por: Myers, G Doug, et al.
Publicado: (2021)

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience
por: Dreger, Peter, et al.
Publicado: (2022)

Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapy
por: Ababneh, Hazim S., et al.
Publicado: (2023)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5go7fjg24d7ae7kb3mlcdjie89